Gain insights into EyePoint Pharmaceuticals' Q2 2025 performance, featuring DURAVYU's Phase III progress in wet-AMD, global expansion, and ...

Bayer AG (BAYRY) reported second-quarter 2025 core earnings of 35 cents per American Depositary Receipt (ADR), which ...

Learn more about whether Amneal Pharmaceuticals, Inc. or Ocular Therapeutix, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Completed Phase 3 enrollment for DURAVYU™ in wet AMD with over 800 patients enrolled and randomized – – LUGANO and LUCIA ...

The eye of the apple snail is unusually similar to a human eye—but, unlike human eyes, it can regrow itself if injured ...

Ocugen says it is on track to reshape the market for gene therapies against eye disorders over the next three years, by ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

Research and development expenses for the second quarter of 2025 were $51.1 million versus $28.9 million for the comparable quarter in 2024, reflecting an increase in overall clinical expenses ...

Pavblu, an Eylea HD biosimilar, shows stable vision outcomes and minimal side effects in real-world use, promising a reliable ...

Investigators defined an IOP spike as >40 mm Hg or an increase ≥10 mm Hg after injection. The population was older (mean age ...

Roche’s Genentech has reported new five-year data from the Phase III Portal trial, confirming the safety, durability, and ...